您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > PRT-060318
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PRT-060318
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PRT-060318图片
CAS NO:1194961-19-7
包装与价格:
包装价格(元)
10 mM * 1 mL in Water电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品名称
PRT318
产品介绍
PRT-060318 (PRT318)是新颖选择性的酪氨酸激酶 (Syk) 抑制剂,IC50值为4 nM。
生物活性

PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinaseSykwith anIC50of 4 nM.

IC50& Target

IC50: 4 nM (Syk)[1]

体外研究
(In Vitro)

PRT318 is a potent inhibitor of purified Syk kinase with an IC50of 4 nM. Syk kinase is inhibited by 92%, whereas all other kinases retains more than 70% at a concentration of 50 nM of PRT318[1]. PRT318 and P505-15 effectively antagonize CLL cell survival after B-cell receptor (BCR) triggering and in nurse-like cell-co-cultures. They inhibit BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT318 and P505-15 inhibit Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering[2].

体内研究
(In Vivo)

PRT318 completely inhibits HIT immune complex-induced aggregation of both human and transgenic HIT mouse platelets. Pretreatment of mice with PRT318 markedly reduces HIT IC-induced thrombosis in the lungs. The Thrombosis Score is significantly lower for PRT318-treated mice compared with control[1].

分子量

340.42

性状

Solid

Formula

C18H24N6O

CAS 号

1194961-19-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

H2O : 5.6 mg/mL(16.45 mM;Need ultrasonic and warming)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.9375 mL14.6877 mL29.3755 mL
5 mM0.5875 mL2.9375 mL5.8751 mL
10 mM0.2938 mL1.4688 mL2.9375 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 25 mg/mL (73.44 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。